Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hormel/Bioenergy deal ended

This article was originally published in The Tan Sheet

Executive Summary

Hormel Foods and Bioenergy, Inc. have terminated their alliance under which Hormel was the exclusive marketer and distributor of Bioenergy's dietary supplement ribose product in the U.S. and Canada. The firms formed the agreement in 1998 (1"The Tan Sheet" Aug. 17, 1998, In Brief)

You may also be interested in...



Bioenergy/Hormel alliance

Hormel Foods Specialty Products Division handling marketing, sales and distribution of Bioenergy's Nutrose D-ribose supplement ingredient. Minneapolis, Minn.-based Bioenergy says the ingredient, a constituent of RNA, is "effective in maintaining and improving the level of adenine nucleotides in heart and skeleton muscle cells following ischemia or decreased blood flow, or strenuous, high-intensity exercise which reduces oxygen availability to the cell." The product may be sold in tablet, capsule or powder form in GNC stores beginning in November. Advertising plans are under development...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel